Atara Biotherapeutics, Inc. (LON:0HIY)
17.81
+2.80 (18.69%)
Jan 9, 2026, 6:00 AM GMT
Atara Biotherapeutics Employees
Atara Biotherapeutics had 153 employees as of December 31, 2024. The number of employees decreased by 72 or -32.00% compared to the previous year.
Employees
153
Change (1Y)
-72
Growth (1Y)
-32.00%
Revenue / Employee
2.97M GBP
Profits / Employee
458.13K GBP
Market Cap
93.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 153 | -72 | -32.00% |
| Dec 31, 2023 | 225 | -109 | -32.63% |
| Dec 31, 2022 | 334 | -244 | -42.21% |
| Dec 31, 2021 | 578 | 141 | 32.27% |
| Dec 31, 2020 | 437 | 44 | 11.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Convatec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
| HUTCHMED (China) | 1,811 |
Atara Biotherapeutics News
- 20 days ago - Atara Biotherapeutics (ATRA) Sees Price Target Increase by Canaccord Genuity | ATRA Stock News - GuruFocus
- 5 weeks ago - Atara Biotherapeutics: An Empty Pipeline With Little Gas - Seeking Alpha
- 2 months ago - Atara Biotherapeutics (ATRA) Reduces Workforce by 29% in Strategic Move - GuruFocus
- 2 months ago - Atara Biotherapeutics (ATRA) Exceeds Q3 Revenue Estimates - GuruFocus
- 2 months ago - Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress - Business Wire
- 2 months ago - Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains? - Nasdaq
- 2 months ago - Atara Biotherapeutics (ATRA) Transfers Key FDA Application to Pierre Fabre - GuruFocus
- 2 months ago - Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PRNewsWire